Previous 10 | Next 10 |
home / stock / tryp:cc / tryp:cc news
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has signed a definitive agreement with Exopharm Limited ACN 163 765 991. The a...
KELOWNA, BC / ACCESSWIRE / December 11, 2023 / Tryp Therapeutics Inc. (" Tryp " or the " Company ") ( CSE:TRYP ), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is pleased...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs. The company today announced that it has closed its private placement of unse...
KELOWNA, BC / ACCESSWIRE / November 20, 2023 / Tryp Therapeutics Inc. (" Tryp " or the " Company ") ( CSE:TRYP ), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has announced a private placement of unsecured convertible notes. The placemen...
KELOWNA, BC / ACCESSWIRE / November 2, 2023 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP ), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is pleased...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has closed its previously announced private placement of unsecured convertible...
KELOWNA, BC / ACCESSWIRE / October 11, 2023 / Tryp Therapeutics Inc. (" Tryp " or the " Company ") ( CSE:TRYP ), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased t...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a clinical-stage biotechnology company dedicated to developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs. The company today announced its appointment of Australia-based Jason Carro...
KELOWNA, BC / ACCESSWIRE / August 3, 2023 / Tryp Therapeutics Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company dedicated to developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is p...
News, Short Squeeze, Breakout and More Instantly...
Tryp Therapeutics Inc. Company Name:
TRYP:CC Stock Symbol:
CNQC Market:
Tryp Therapeutics Inc. Website:
Kelowna, British Columbia--(Newsfile Corp. - May 17, 2024) - Tryp Therapeutics, Inc. (CSE: TRYP) (" Tryp " or the " Company ") announces, that it has filed amended financial statements for the six months ended February 29, 2024 (the " Financial Statements "), along with the corresponding Manage...
KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP, OTCQB: TRYPF ) and Exopharm Limited ACN 163 765 991 (" Exopharm ") are pleased to announce that completion of the previously announced plan of arrangement (the " Arrangement ") effective ...
Toronto, Ontario--(Newsfile Corp. - Le 24 avril/April 2024) - Tryp Therapeutics Inc. (the "Issuer") has announced that further to the press release dated February 8, 2024, the shareholders of Exopharm Limited ACN 163 765 991 have approved the previously announced plan of arrangement (the “...